Dr. Philip L. Shettle, D.O.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 784
Licensed in Colorado since 1993, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
FL license OS 6621 · CO license 32591 (first issued 1993; expired) · MI license 5101010879
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 784
- Services billed
- 1,959
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient complete exam of visual system | 909 | 626 |
| Exam of visual field with extended testing | 179 | 169 |
| Imaging of optic nerve | 162 | 161 |
| Established patient problem focused exam of visual system | 131 | 93 |
| New patient office or other outpatient visit, 45-59 minutes | 95 | 95 |
| New patient complete exam of visual system | 87 | 87 |
| Photography of the retina | 86 | 85 |
| Imaging of retina | 82 | 81 |
| Removal of cataract with insertion of prosthetic lens | 34 | 25 |
| Measurement of retinal and optic nerve function | 28 | 28 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Latanoprost Other prescribers in Largo, FL | 419 |
| Timolol Maleate Other prescribers in Largo, FL | 99 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Largo, FL | 68 |
| Prednisolone Acetate Other prescribers in Largo, FL | 65 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Largo, FL | 47 |
| Brimonidine Tartrate Other prescribers in Largo, FL | 41 |
| Restasis (cyclosporine) Other prescribers in Largo, FL | 39 |
| Moxifloxacin (moxifloxacin hcl) Other prescribers in Largo, FL | 31 |
| Lumigan (bimatoprost) Other prescribers in Largo, FL | 30 |
| Cequa (cyclosporine) Other prescribers in Largo, FL | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 25 payments worth $1,236 in total to this clinician.
| Bausch & Lomb Americas Inc. | $795 |
|---|---|
| Mallinckrodt Hospital Products Inc. | $220 |
| Sun Pharmaceutical Industries Inc. | $82.02 |
| Dompe US, Inc. | $62.51 |
| Glaukos Corporation | $38.07 |
| Harrow Eye, LLC | $19.71 |
| AbbVie Inc. | $18.82 |
| Food and Beverage | $1,236 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $173,488 in research payments for these studies, mostly to the institutions running them.
- Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
Oyster Point Pharma, Inc. · Completed · NCT06349759 - A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
Oyster Point Pharma, Inc. · Terminated · NCT06400511 - Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
Oyster Point Pharma, Inc. · Completed · NCT06542497 - M23-730 - A Multicenter, Double-masked, Randomized Study to Compare the Efficacy and Safety of the ABBV-444 Tear Formulation with REFRESH OPTIVE Unit Dose in Patients with Dry Eye Disease
AbbVie Inc. - A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
AbbVie Inc. · Completed · NCT07284381
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.